Dire Wolves! They're Back?

What It Covers

Colossal Biosciences claims to have resurrected dire wolves by editing 14 gray wolf genes, raising $400 million and achieving a $10 billion valuation, but scientists question whether these modified animals are truly dire wolves.

Key Questions Answered

• •Gene Editing Limitations: Colossal modified only 15 of 80 potential dire wolf genes in gray wolves, deliberately avoiding five genes that would cause deafness and blindness, demonstrating how genetic engineering creates unpredictable health problems in de-extinct animals.
• •Space Constraints: The engineered wolves occupy approximately three square miles while natural wolves require 50 to 1,000 square miles of territory, creating welfare concerns about confinement and preventing any realistic reintroduction into wild ecosystems for environmental benefit.
• •Business Model Reality: The company plans to profit from spinning off biomedical technology developed during de-extinction research rather than displaying animals, with investors treating this as a tech venture comparable to cryptocurrency rather than conservation funding.
• •Regulatory Vacuum: No government regulations currently govern de-extinction processes despite animal welfare concerns throughout breeding, with the Trump administration suggesting de-extinction eliminates the need for endangered species protections, allowing extinction without consequences.